CD36 and Alzheimer disease: Furthermore, miR-485-3p was overexpressed in patients with AD, and it inhibited microglial Aβ phagocytosis by directly interacting with CD36, resulting in impaired Aβ clearance during AD progression; these results suggest that miR-485-3p acts as a biomarker of AD that triggers AD pathology.